AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05701020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnary
Description: If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
Study NCT04920578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-69095897
Description: JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
Study NCT04920578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally in Parts 1 and 3.
Study NCT04912726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Injectable Product
Description: The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
Study NCT05485415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal intervention
Description: Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
Study NCT04800848 — intervention group
Intervention type: DEVICE
Intervention: Mask
Description: Physical Fitness is evaluated with the use of a face mask
Study NCT05727735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Signia Stapler
Description: The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
Study NCT05727735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling
Description: The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
Study NCT05246371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol, dexmedetomidine
Description: Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
Study NCT05485415 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General sleep advice
Study NCT05246371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Patients will receive maintenance of general anesthesia by desflurane.
Study NCT06263816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Patients will be treated with carvedilol.
Description: Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
Study NCT06263816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group: Patients will receive a placebo.
Description: Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
Study NCT05121948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
Study NCT04522596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol 55/22 μg inhaled once a day
Study NCT04522596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once a day
Study NCT05149534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Narrative written disclosure of trauma administered in an evidence-based protocol.
Study NCT05149534 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Written Exposure Therapy
Description: Narrative written disclosure of trauma administered in an evidence-based protocol.
Study NCT05149534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Noninvasive magnetic neuromodulation device
Study NCT05149534 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Noninvasive magnetic neuromodulation device
Study NCT06042634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducation
Description: Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
Study NCT06042634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation
Description: Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
Study NCT05629260 — intervention group
Intervention type: DRUG
Intervention: ATG
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
Study NCT05629260 — intervention group
Intervention type: DRUG
Intervention: Post-transplantation cyclophosphamide
Description: Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
Study NCT05677282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Rifaximin 550 mg as a single dose administered orally.
Study NCT05677282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 MG
Description: Azithromycin 500 mg as a single dose administered orally.
Study NCT05677282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
Study NCT05677282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: 4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
Study NCT06114888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV + Usual Care
Description: We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
Study NCT06114888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Alone
Description: Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
Study NCT05213702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Calyx punture with traditional free hand or ANT-X device
Description: ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
Study NCT05699824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Day2
Description: Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
Study NCT05699824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
Study NCT05699824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
Study NCT05699824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol Day6
Description: Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
Study NCT05181644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED treatment
Description: Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
Study NCT05181644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current Standard of Care
Description: The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
Study NCT05181644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: current Standard of Care
Description: The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
Study NCT05766826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coupons for safe water program: Treatment
Description: Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
Study NCT05766826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coupons for safe water program: Control
Description: Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
Study NCT05270837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Description: Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
Study NCT05270837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet Only
Description: Diet Control
Study NCT04120415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine and vedolizumab (Entyvio)
Description: Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
Study NCT04120415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo vaccine and vedolizumab infusion (Entyvio)
Description: Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion.
Study NCT04120415 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine and placebo infusion
Description: Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion.
Study NCT05809193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy
Description: After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response.
Study NCT05021770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150mg or 200mg orally daily
Study NCT05021770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: RP2D
Study NCT05021770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
Study NCT04248127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey sweetened yogurt
Description: 2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
Study NCT04248127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar sweetened yogurt
Description: sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
Study NCT04880655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSD
Description: Post debridement and within 24 hours of injury, wound care and WSD applied daily
Study NCT04880655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressed with bacitracin and petrolatum gauze
Description: Post debridement and within 24 hours of injury, wound care and dressing applied daily
Study NCT05439356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Study NCT05439356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo colchicine
Description: Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Study NCT06471218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918; SHR-1918 Placebo
Description: SHR-1918/SHR-1918 Placebo,two administration
Study NCT06073652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control 1st age starter infant formula
Description: A standard bovine milk-based term infant formula.
Study NCT06073652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1st age starter infant formula
Description: Same content as Control formula plus supplemented with a HMO blend and a probiotic
Study NCT05018715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine learning model diagnosis
Description: Machine learning model diagnosis
Study NCT05851144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bienestar/Neema Coordinated School Health Program (BN CSHP)
Description: Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
Study NCT06261515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active periodontal treatment
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
Study NCT03158857 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir 400 mg
Description: These drugs are being offered as part of routine care
Study NCT05850156 — intervention group
Intervention type: PROCEDURE
Intervention: basal blood collection
Description: blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
Study NCT05850156 — intervention group
Intervention type: PROCEDURE
Intervention: blood collection M6
Description: 6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
Study NCT05850156 — intervention group
Intervention type: PROCEDURE
Intervention: blood collection M12
Description: 12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: the usage and dosage should be determined by the investigator
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: the usage and dosage should be determined by the investigator
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab Injection
Description: Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: the usage and dosage should be determined by the investigator
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: the usage and dosage should be determined by the investigator
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection
Description: the usage and dosage should be determined by the investigator
Study NCT06123884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel for Injection
Description: the usage and dosage should be determined by the investigator
Study NCT04787575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy
Description: Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas
Study NCT04787575 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oxygen-ozone therapy
Description: Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas